Case Reports in Oncological Medicine最新文献_第6页

Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer. 药物在控制铂耐药透明细胞卵巢癌复发中的作用。

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2023-01-01 DOI: 10.1155/2023/2079654

Woraporn Sinsuwan, Phawit Norchai

{"title":"Repurposing Drugs in Controlling Recurrent Platinum-Resistant Clear-Cell Ovarian Cancer.","authors":"Woraporn Sinsuwan, Phawit Norchai","doi":"10.1155/2023/2079654","DOIUrl":"https://doi.org/10.1155/2023/2079654","url":null,"abstract":"Background: Recurrent platinum-resistant clear-cell ovarian cancer has a low overall survival duration of 7-8 months, making it a fatal disease. Currently, chemotherapy is the major kind of treatment, but it offers little advantage. Repurposed conventional drugs have recently been found to offer the ability to control cancer with few side effects and at a reasonable cost to healthcare organizations. Case Presentation. In this case report, we present the case of a 41-year-old Thai female patient diagnosed with recurrent platinum-resistant clear-cell ovarian cancer (PRCCC) in the year 2020. After undergoing chemotherapy for two courses and failing to respond to treatment, she began alternative medicine with repurposing drugs in November 2020. Simvastatin, metformin, niclosamide, mebendazole, itraconazole, loratadine, and chloroquine were also administered. Two months after therapy, a computerized tomography (CT) scan revealed a conflict between a decline in tumor marker levels (CA 125, CA 19-9) and an increase in the number of lymph nodes. However, after continuing all medications for 4 months, the CA 125 level decreased from 303.6 to 54 U/ml, and the CA 19-9 level decreased from 1210.3 to 386.10 U/ml. The patient's EQ-5D-5L score increased from 0.631 to 0.829 (abdominal pain and depression), indicating improved quality of life. Overall survival was 8.5 months, and progression-free survival was 2 months.Conclusion: The response to drug repurposing is demonstrated by a four-month-long improvement in symptoms. This work introduces a novel strategy for the management of recurrent platinum-resistant clear-cell ovarian cancer that needs further evaluation in large-scale studies.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2023 ","pages":"2079654"},"PeriodicalIF":0.9,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10028782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of Merkel Cell Carcinoma in a Patient Receiving Rituximab. 接受利妥昔单抗的患者发生默克尔细胞癌。

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-11-03 eCollection Date: 2022-01-01 DOI: 10.1155/2022/1814338

Bana Antonios, Ujjwal Karki, Kais Antonios, Bipin Ghimire, Mohammad Muhsin Chisti

{"title":"Development of Merkel Cell Carcinoma in a Patient Receiving Rituximab.","authors":"Bana Antonios, Ujjwal Karki, Kais Antonios, Bipin Ghimire, Mohammad Muhsin Chisti","doi":"10.1155/2022/1814338","DOIUrl":"https://doi.org/10.1155/2022/1814338","url":null,"abstract":"Merkel cell carcinoma (MCC) is a rare, rapidly growing, and aggressive dermatological neoplasm. It is commonly reported in Caucasian ethnicities, and almost 50% of the patients have a concomitant malignancy and are on immunosuppressive chemotherapy. Here, we present a 79-year-old woman with a history of relapsed Stage II, grade III follicular lymphoma, receiving maintenance rituximab infusions. She presented with a raised erythematous papule on her left cheek. An excisional biopsy of the lesion confirmed a diagnosis of Merkel cell carcinoma. After which, she underwent a wider excision with 1-2 cm margins. PET scan did not reveal any FDG-avid uptake lesions that would be concerning for metastatic disease. However, she underwent a sentinel lymph node biopsy which was also negative. Thus, the diagnosis was finalized as Stage I (T1 N0 M0) MCC. There are only two reported cases in literature about the significant progression of Merkel cell carcinoma in patients who coincidentally were receiving rituximab as a part of treatment for another disease. This raises questions for future investigation and research on whether there is a direct association between rituximab use specifically and the rapid growth of MCC.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":" ","pages":"1814338"},"PeriodicalIF":0.9,"publicationDate":"2022-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649309/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40471622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Acute Adrenal Hemorrhage as the Initial Manifestation of Metastatic Lung Adenocarcinoma: A Cautionary Tale. 急性肾上腺出血是转移性肺腺癌的最初表现:一个警世故事。

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-10-25 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2864773

Sowbharnika Arivazhagan, Guru Prasad Parthiban, Christina Patterson, Karthik Reddy

引用次数: 0

A South African Breast Implant-Associated Anaplastic Large Cell Lymphoma: Clinical Presentation and Six-Year Follow-Up 一例南非乳房植入相关的整形不全大细胞淋巴瘤的临床表现和六年随访

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-05-31 DOI: 10.1155/2022/4162832

Alexandra Grubnik, Y. Ramdas, Barend Van der Bergh, S. Nayler, C. Benn, B. Rapoport

{"title":"A South African Breast Implant-Associated Anaplastic Large Cell Lymphoma: Clinical Presentation and Six-Year Follow-Up","authors":"Alexandra Grubnik, Y. Ramdas, Barend Van der Bergh, S. Nayler, C. Benn, B. Rapoport","doi":"10.1155/2022/4162832","DOIUrl":"https://doi.org/10.1155/2022/4162832","url":null,"abstract":"Breast augmentation is the most common surgical procedure for women globally, with 1,795,551 cases performed in 2019. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is highly uncommon, with 733 reported cases as of January 2020. In South Africa, there are less than 4000 breast augmentation surgeries annually. This case presents the first case report documentation of a South African woman diagnosed with BIA-ALCL. The patient was a 61-year-old woman who consulted the Breast Care Centre of Excellence in Johannesburg in 2015. She had a prior history of bilateral augmentation mammoplasty with subsequent implant exchange. The patient presented with periprosthetic fluid with a mass-like enhancement on the left breast. Aspiration of the mass-like fluid was positive for CD45, CD30, and CD68 and negative for CD20 and ALK-1, indicative of BIA-ALCL. Surgical treatment included bilateral explantation, complete capsulectomies, and bilateral mastopexy. Macroscopic examination of the left breast capsulectomy demonstrated fibrous connective tissue. The histological examination of the tumor showed extensive areas of broad coagulative necrosis with foamy histiocytes. Immunohistochemistry examination of this tumor showed CD3-, CD20-, and ALK-1-negative and CD30- and CD68-positive stains. PCR analysis for T-cell clonality showed monoclonal T-cell expansion. These findings confirm the presence of BIA-ALCL. The patient recovered well after surgery and did not require adjuvant therapy. A patient with a confirmed diagnosis of BIA-ALCL was successfully treated with explantation and complete capsulectomy. She was followed up regularly for six years, and the patient remains well and in remission.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48549141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Surgical Treatment of Single Pontomedullary Junction Metastasis from Lung Cancer 癌症单桥髓核交界转移的外科治疗

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-05-31 DOI: 10.1155/2022/4041506

P. Missori, S. Peschillo, A. Ambrosone, A. Currà, S. Paolini

引用次数: 0

A Rare Case of Pure Primary Large Cell Neuroendocrine Carcinoma of the Gallbladder 罕见的单纯原发性胆囊大细胞神经内分泌癌

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-05-21 DOI: 10.1155/2022/6956046

R. Shackelford, E. Ozluk, J. Abdulsattar, T. Lairmore, Quyen Chu, E. Wei

引用次数: 0

A Pulmonary Zebra: Adult Primary Pulmonary Synovial Sarcoma 肺斑马:成人原发性肺滑膜肉瘤

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-04-16 DOI: 10.1155/2022/8649540

Sheffield Sandra, Nwachukwu Chidi, Ashby Tracy

引用次数: 0

A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim 检查点抑制剂治疗和培非司汀治疗后罕见的大血管血管炎

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-02-23 DOI: 10.1155/2022/7295305

J. Mort, Shipra Maheshwari, Nayanika Basu, P. Dillon, Kevin Brady, H. Bear, T. Millard

{"title":"A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim","authors":"J. Mort, Shipra Maheshwari, Nayanika Basu, P. Dillon, Kevin Brady, H. Bear, T. Millard","doi":"10.1155/2022/7295305","DOIUrl":"https://doi.org/10.1155/2022/7295305","url":null,"abstract":"Checkpoint inhibitors (CPIs) and pegfilgrastim, a long-acting growth factor agent, are vital components of current cancer treatments. Immune-related adverse events (irAEs) such as colitis and pneumonitis are well-established toxicities associated with CPI therapy. However, large-vessel vasculitis secondary to CPI utilization is reported only in rare case reports and case series. Interestingly, large-vessel vasculitis has also been reported as a rare complication of pegfilgrastim use. We present a 59-year-old female with left stage IIA (cT2N0M0) triple-negative breast cancer receiving neoadjuvant decitabine and pembrolizumab prior to neoadjuvant chemotherapy (NAC). NAC included standard-of-care dose dense doxorubicin and cyclophosphamide (ddAC) supported with pegfilgrastim use followed by weekly carboplatin and paclitaxel. After receiving her second cycle of ddAC with pegfilgrastim, the patient reported five days of left shoulder and arm pain. Subsequent CT imaging demonstrated wall thickening and inflammatory changes surrounding the left subclavian artery, aortic arch, left carotid artery, proximal innominate arteries, and the mid internal carotid arteries and its branching vessels. These findings were extremely concerning for large-vessel vasculitis. Excluding CPI therapy and pegfilgrastim use, no additional inciting event or medication that the patient was exposed to was noted to be associated with large-vessel vasculitis. We present this case to report on this rare but severe complication from commonly utilized agents in cancer treatment. We also extend the possibility of large-vessel vasculitis development in relation to the COVID-19 vaccine due to shared ingredients found in both the vaccine and pegfilgrastim. It is important to outline the treatment used for such a complication as no standardized treatment has been established for large-vessel vasculitis caused by CPI therapy or pegfilgrastim use.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2022-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42912710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer. 阿特唑单抗诱导转移性乳腺癌患者结节病样反应

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-01-27 eCollection Date: 2022-01-01 DOI: 10.1155/2022/2709062

Akira Tsunoda, Toshiro Mizuno, Shohei Iida, Katsunori Uchida, Masako Yamashita, Koshi Sukeno, Hiroki Oka, Yasutaka Tono, Mikiya Ishihara, Kanako Saito, Satoshi Tamaru, Keiichi Yamanaka, Isao Tawara

{"title":"Atezolizumab-Induced Sarcoidosis-Like Reaction in a Patient with Metastatic Breast Cancer.","authors":"Akira Tsunoda, Toshiro Mizuno, Shohei Iida, Katsunori Uchida, Masako Yamashita, Koshi Sukeno, Hiroki Oka, Yasutaka Tono, Mikiya Ishihara, Kanako Saito, Satoshi Tamaru, Keiichi Yamanaka, Isao Tawara","doi":"10.1155/2022/2709062","DOIUrl":"https://doi.org/10.1155/2022/2709062","url":null,"abstract":"Tumor-related sarcoidosis-like reactions (SLR) have been reported with the use of immune checkpoint inhibitors (ICIs). We report a case of 50-year-old woman who observed an enlarged lymph node in the right hilar region and the appearance of a subcutaneous mass in the extremities during chemotherapy with atezolizumab plus nab-paclitaxel for metastatic triple-negative breast cancer (TNBC). Skin biopsy revealed the formation of epithelioid granulation species with the Langhans giant cell. After discontinuing atezolizumab in the treatment procedure, the hilar lymph nodes and the subcutaneous mass were reduced. A pathological examination was effective in differentiating tumor exacerbation from SLR. Owing to limited information on ICI-related SLR in breast cancer, future studies are recommended to properly manage immune-related adverse effects during cancer treatment.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":" ","pages":"2709062"},"PeriodicalIF":0.9,"publicationDate":"2022-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8813290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39756925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Primary Eccrine Porocarcinoma of the Breast: A Case Report and Review of Literature. 乳腺原发性内分泌性多孔癌1例报告及文献复习。

IF 0.9

Case Reports in Oncological Medicine Pub Date : 2022-01-01 DOI: 10.1155/2022/4042298

Yi Xin Li, Mihir Gudi, Zhiyan Yan

{"title":"Primary Eccrine Porocarcinoma of the Breast: A Case Report and Review of Literature.","authors":"Yi Xin Li, Mihir Gudi, Zhiyan Yan","doi":"10.1155/2022/4042298","DOIUrl":"https://doi.org/10.1155/2022/4042298","url":null,"abstract":"Eccrine porocarcinoma (EPC) is a rare cutaneous neoplasm, with less than 500 reported cases worldwide since it was first described in 1963. EPC tends to affect the elderly and most commonly affects the head and neck. The mainstay of EPC treatment is surgery, with lymphadenectomy in the case of nodal involvement or presence of unfavourable characteristics. No evidence exists to guide the use of adjuvant chemotherapy or radiation. EPC is prone to misdiagnosis given its multiple clinical and histopathological mimics, especially in uncommon sites of presentation such as the breast. Herein, we report the case of a 59-year-old woman who presented with a left breast skin lump. The biopsied specimen revealed an infiltrative carcinoma involving the dermis and epidermis with positive IHC staining for P63 and CK5/6 and negative staining for ER, PR, and HER2. The tumour was resected and diagnosed as EPC with atypical features as overlapping characteristics of squamous cell carcinoma (SCC) were detected on histopathological analysis. In our case, a simple mastectomy with broad margins and axillary lymph node dissection with adjuvant radiotherapy to a dose of 60 Gy failed to achieve loco-regional control with nodal recurrence occurring 4 months postsurgery-a testament to the aggressive course of this rare malignancy.","PeriodicalId":9636,"journal":{"name":"Case Reports in Oncological Medicine","volume":"2022 ","pages":"4042298"},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9173910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10257503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0